ATE550030T1 - Neue verwendung von antisekretorischem faktor - Google Patents

Neue verwendung von antisekretorischem faktor

Info

Publication number
ATE550030T1
ATE550030T1 AT04775470T AT04775470T ATE550030T1 AT E550030 T1 ATE550030 T1 AT E550030T1 AT 04775470 T AT04775470 T AT 04775470T AT 04775470 T AT04775470 T AT 04775470T AT E550030 T1 ATE550030 T1 AT E550030T1
Authority
AT
Austria
Prior art keywords
cell
condition
stem cell
disease
antisecretoric
Prior art date
Application number
AT04775470T
Other languages
English (en)
Inventor
Hans-Arne Hansson
Eva Jennische
Stefan Lange
Ivar Loennroth
Peter Eriksson
Anders Persson
Original Assignee
Faktor Ab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faktor Ab As filed Critical Faktor Ab As
Application granted granted Critical
Publication of ATE550030T1 publication Critical patent/ATE550030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
AT04775470T 2003-09-26 2004-09-24 Neue verwendung von antisekretorischem faktor ATE550030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322645.3A GB0322645D0 (en) 2003-09-26 2003-09-26 Use of antisecretory factor peptides
PCT/SE2004/001369 WO2005030246A1 (en) 2003-09-26 2004-09-24 Novel use of antisecretory factor

Publications (1)

Publication Number Publication Date
ATE550030T1 true ATE550030T1 (de) 2012-04-15

Family

ID=29286947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775470T ATE550030T1 (de) 2003-09-26 2004-09-24 Neue verwendung von antisekretorischem faktor

Country Status (18)

Country Link
US (2) US20070009575A1 (de)
EP (1) EP1734989B1 (de)
JP (1) JP4943847B2 (de)
KR (1) KR101159858B1 (de)
CN (2) CN103028110B (de)
AT (1) ATE550030T1 (de)
AU (1) AU2004275682B2 (de)
BR (1) BRPI0414793A (de)
CA (1) CA2537335C (de)
DK (1) DK1734989T3 (de)
ES (1) ES2384385T3 (de)
GB (1) GB0322645D0 (de)
IL (1) IL174464A (de)
NO (1) NO340187B1 (de)
NZ (1) NZ545661A (de)
RU (1) RU2416426C2 (de)
WO (1) WO2005030246A1 (de)
ZA (1) ZA200601807B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
PL2040734T3 (pl) 2006-04-27 2012-04-30 Lantmaennen As Faktor Ab Białko przeciwwydzielnicze do zastosowania w leczeniu zespołu przedziału
KR20090037992A (ko) * 2006-04-27 2009-04-17 란트만넨 아스-팍토르 아베 항분비 단백질의 추가적 의학 용도
AU2012201165B2 (en) * 2006-04-27 2013-12-19 Lantmannen As-Faktor Ab New approach to treat intraocular hypertension
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
JP5820277B2 (ja) 2009-02-11 2015-11-24 ラントメネン・アーエス−ファクトール・アーベー 細胞取込を最適化するための抗分泌性因子（ａｆ）の使用
ITMI20120008A1 (it) * 2012-01-04 2013-07-05 Biava Maura Composizioni ad attività anti-neurodegenerativa
US9738553B2 (en) * 2012-03-16 2017-08-22 Aquatech International, Llc Process for purification of produced water
US20150183850A1 (en) * 2012-05-18 2015-07-02 University Of Iowa Research Foundation Methods and compositions for treating amyloid deposits
NZ708860A (en) * 2012-12-20 2016-09-30 Lantmännen As Faktor Ab Use of antisecretory factor (af) in glioblastoma treatment
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065091A1 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted wheat
CN112770643A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
EP4125984A1 (de) * 2020-03-26 2023-02-08 Lantmännen Functional Foods AB Verzehrbares produkt mit mälzten getreiden zur förderung der erholung bei körperlicher aktivität
CN112006035B (zh) * 2020-07-24 2021-07-30 江西新龙生物科技股份有限公司 用于防治植物病害的微生物源杀菌剂及其制备方法
WO2026099453A1 (en) 2024-11-07 2026-05-15 Lantmännen Medical Ab Af-16 or af-17 for acute treatment of brain oedema in patients with traumatic brain injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566455B1 (en) * 1995-06-07 2009-07-28 Gpc Biotech, Inc. E6AP-binding proteins
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
WO1997027296A1 (en) * 1996-01-26 1997-07-31 Hsc Research And Development Limited Partnership Nucleic acids and proteins related to alzheimer's disease, and uses therefor
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
AU5627000A (en) * 1999-06-21 2001-02-05 Inkine Pharmaceutical Company, Inc. Angiocidin: a CYS-SER-VAL-THR-CYS-GLY specific tumor cell adhesion receptor
EP1350847A4 (de) * 2001-01-09 2005-12-28 Inst Of Gene And Brain Science Menschliches gliomantigen und verfahren zu dessen herstellung
WO2003063688A2 (en) * 2002-01-25 2003-08-07 Incyte Corporation Protein modification and maintenance molecules

Also Published As

Publication number Publication date
GB0322645D0 (en) 2003-10-29
US20070009575A1 (en) 2007-01-11
US8748367B2 (en) 2014-06-10
EP1734989B1 (de) 2012-03-21
CN103028110B (zh) 2016-02-17
JP2007506735A (ja) 2007-03-22
IL174464A (en) 2015-08-31
AU2004275682A1 (en) 2005-04-07
BRPI0414793A (pt) 2006-11-21
AU2004275682B2 (en) 2010-01-28
ES2384385T3 (es) 2012-07-04
KR20060097718A (ko) 2006-09-14
EP1734989A1 (de) 2006-12-27
CN1856320A (zh) 2006-11-01
CN103028110A (zh) 2013-04-10
US20100286052A1 (en) 2010-11-11
IL174464A0 (en) 2006-08-01
WO2005030246A1 (en) 2005-04-07
NZ545661A (en) 2009-10-30
ZA200601807B (en) 2007-06-27
NO340187B1 (no) 2017-03-20
JP4943847B2 (ja) 2012-05-30
CA2537335C (en) 2017-12-05
RU2416426C2 (ru) 2011-04-20
DK1734989T3 (da) 2012-07-09
RU2006114030A (ru) 2007-11-20
CA2537335A1 (en) 2005-04-07
NO20060901L (no) 2006-06-20
KR101159858B1 (ko) 2012-06-25

Similar Documents

Publication Publication Date Title
NO20060901L (no) Ny anvendelse av antisekretorisk faktor
Schlender et al. Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro
Allocati et al. p63/p73 in the control of cell cycle and cell death
Zheng et al. Ginkgolide B promotes the proliferation and differentiation of neural stem cells following cerebral ischemia/reperfusion injury, both in vivo and in vitro
ATE139261T1 (de) Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
Li et al. Identification of 14-3-3σ mutation causing cutaneous abnormality in repeated-epilation mutant mouse
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
Jin et al. Amniotic epithelial cells promote wound healing in mice through high epithelialization and engraftment
ATE195149T1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
DE59507920D1 (de) NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
DE69100364D1 (de) Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.
ATE548049T1 (de) Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung
WO2005046570A3 (en) Human stem cell materials and methods
ATE265226T1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
DE69726884D1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
DE69930662D1 (de) Humane rezeptortyrosinkinase
Mendes‐da‐Cruz et al. Neuropilins, semaphorins, and their role in thymocyte development
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
PT914419E (pt) Ratinhos transgenicos capazes de expressar o factor de inibicao de leucemia
DE60206037D1 (de) Lektin-ähnliche domäne von thrombomodulin und therapeutische verwendung davon
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE602005018683D1 (de) Herstellung von 1,4-butandiol und/oder 2-methyl 1,3-propandiol
ATE281165T1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
ATE322906T1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten